Chengzhi Zhou

机构：Central South University, First Affiliated Hospital of Guangzhou Medical University, Hunan Cancer Hospital, Guangzhou Development Zone Hospital, State Key Laboratory of Respiratory Disease, Guangzhou Medical University · ORCID：0000-0003-0029-6879

发表论文 317 篇 · 总被引 6404 次 · h-index 43

代表论文

• Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS) (2026 · Nature Communications · 被引 5)
• International guidelines on the diagnosis and treatment of NUT carcinoma (2025 · The Innovation · 被引 5)
• Sintilimab plus chemotherapy for first-line treatment of advanced pulmonary lymphoepithelioma-like carcinoma: Phase 2 trial (2025 · Cell Reports Medicine · 被引 4)
• Association between EGFR mutation types and incidence of brain metastases in postoperative patients with stage I–III NSCLC (2025 · Tumori Journal · 被引 4)
• Expert Consensus on the Diagnosis and Treatment of Malignant Mesothelioma of the Tunica Vaginalis Testis (2025 · iMetaMed · 被引 3)
• The survival analysis of stage III and IV inoperable lung large cell neuroendocrine carcinoma and the role of LIPI in immunological stratification (2025 · Lung Cancer · 被引 3)